Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CollPlant Biotechnologies (CLGN) Cash from Operations (2018 - 2025)

Historic Cash from Operations for CollPlant Biotechnologies (CLGN) over the last 8 years, with Q3 2025 value amounting to -$2.9 million.

  • CollPlant Biotechnologies' Cash from Operations rose 1656.03% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.9 million, marking a year-over-year increase of 2332.36%. This contributed to the annual value of -$14.1 million for FY2024, which is 41006.15% down from last year.
  • According to the latest figures from Q3 2025, CollPlant Biotechnologies' Cash from Operations is -$2.9 million, which was up 1656.03% from -$2.4 million recorded in Q2 2025.
  • CollPlant Biotechnologies' Cash from Operations' 5-year high stood at $11.1 million during Q1 2021, with a 5-year trough of -$13.7 million in Q4 2022.
  • Over the past 5 years, CollPlant Biotechnologies' median Cash from Operations value was -$3.2 million (recorded in 2022), while the average stood at -$2.4 million.
  • As far as peak fluctuations go, CollPlant Biotechnologies' Cash from Operations skyrocketed by 53009.67% in 2021, and later tumbled by 46603.31% in 2022.
  • Over the past 5 years, CollPlant Biotechnologies' Cash from Operations (Quarter) stood at -$2.4 million in 2021, then crashed by 466.03% to -$13.7 million in 2022, then soared by 82.88% to -$2.3 million in 2023, then plummeted by 47.72% to -$3.5 million in 2024, then rose by 16.95% to -$2.9 million in 2025.
  • Its Cash from Operations was -$2.9 million in Q3 2025, compared to -$2.4 million in Q2 2025 and -$1.2 million in Q1 2025.